Molecular Templates (NASDAQ:MTEM) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday, February 2nd.
Other research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Molecular Templates from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 31st. Zacks Investment Research upgraded shares of Molecular Templates from a “sell” rating to a “hold” rating in a report on Wednesday, January 17th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Molecular Templates has a consensus rating of “Hold” and a consensus target price of $5.20.
Molecular Templates (NASDAQ:MTEM) opened at $8.86 on Friday. Molecular Templates has a 1 year low of $3.85 and a 1 year high of $13.25. The company has a market cap of $228.74, a P/E ratio of -5.24 and a beta of 3.07. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16.
Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new position in shares of Molecular Templates during the 4th quarter worth about $722,000. Lyon Street Capital LLC bought a new position in shares of Molecular Templates during the 4th quarter worth about $557,000. Alps Advisors Inc. bought a new position in shares of Molecular Templates during the 4th quarter worth about $298,000. OxFORD Asset Management LLP bought a new position in shares of Molecular Templates during the 3rd quarter worth about $140,000. Finally, BlueCrest Capital Management Ltd bought a new position in shares of Molecular Templates during the 4th quarter worth about $157,000. 14.70% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/18/molecular-templates-mtem-upgraded-to-hold-by-valuengine.html.
About Molecular Templates
Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.